Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma.

CONCLUSIONS: These results from an integrated analysis support a favorable benefit/risk profile of daratumumab in patients with MM. PMID: 32409106 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research